Rhinorus, spray 0,05%, 20ml

Composition

Active ingredient:

xylometazoline hydrochloride 0.5 mg;

Auxiliary substances:

benzalkonium chloride,

sodium chloride,

disodium edetate,

sodium dihydrogen phosphate dihydrate,

sodium hydrophosphate dodecahydrate,

eucalyptus oil,

d/i water.

Pharmacological action

Pharmacotherapeutic group: anticongestive agent-alpha-adrenomimetic ATX code: R01AA07 Pharmacodynamics :

Vasoconstrictor drug for topical use in ENT practice (decongestant).

Xylometazoline (an imidazoline derivative) is an alpha-adrenomimetic. Causes narrowing of the blood vessels of the nasal mucosa. Restores the patency of the nasal passages, quickly facilitates nasal breathing and improves the discharge of nasal secretions in rhinitis (runny nose) of various origins.

The effect of the drug occurs 5-10 minutes after its application and lasts up to 10 hours.

Pharmacokinetics:

When applied topically, xylometazoline is practically not absorbed, so its concentration in blood plasma is very low (it is not determined by modern analytical methods).

Indications

• acute rhinitis (including against the background of acute respiratory diseases and allergic rhinitis);
• sinusitis;
• eustachiitis;
• runny nose with allergies and colds;
• otitis media (as part of combination therapy to reduce swelling of the nasopharyngeal mucosa);
• to facilitate rhinoscopy;
• preparation of patients for diagnostic manipulations in the nasal passages.

Contraindications

• hypertension;
• tachycardia;
• severe atherosclerosis;
• glaucoma;
• atrophic rhinitis;
• hyperthyroidism;
• surgical interventions on the meninges (history);
• pregnancy (for nasal drops);
• children’s age up to 2 years old;
• children up to age 6 years (for nasal drops 0.1% and nasal spray 0.1%);
• hypersensitivity to product components (including the oil of eucalyptus).

Do not use in therapy with MAO inhibitors and tricyclic antidepressants, as well as with other drugs that increase blood pressure.

With caution, the drug should be prescribed for diabetes mellitus, coronary heart disease, angina pectoris of functional class III-IV, prostatic hyperplasia, during lactation.

Side effects

Local reactions:  with frequent and/or prolonged use – irritation and/or dryness of the nasopharyngeal mucosa, burning, paresthesia, sneezing, hypersecretion; rarely – swelling of the nasal mucosa.

Systemic reactions:  vomiting, headache, palpitation, increased blood pressure, insomnia, visual impairment, depression (with prolonged use of high doses).

Interaction

It is possible to increase the systemic effect with simultaneous use of monoamine oxidase (MAO) inhibitors and tricyclic antidepressants.

How to take, course of use and dosage

Adults and children over 6 years of age – 1 injection of 0.1% nasal spray in each nasal passage 3 times / day. If necessary, you can repeat the injection (no more than two injections at a time).

Children from 2 to 6 years – 1 injection of 0.05% nasal spray in each nasal passage 1-2 times / day.

Do not use the drug more than 3 times a day. The duration of treatment is no more than 5-7 days (without a break).

After the end of therapy, the drug can be prescribed again only after a few days.

The duration of use of the drug in children is determined by the doctor.

Overdose

Symptoms:  increased side effects.

Treatment:  symptomatic under the supervision of a doctor.

Special instructions

Do not exceed the recommended dose and use for a long time. Before use, it is necessary to clean the nasal passages. Do not apply for more than 7 days.

Form of production

Spray

Storage conditions

In a dry place, protected from light, at a temperature not exceeding 25 °C.

Shelf life

2 years

Active ingredient

Xylometazoline

Dosage Form

Spray nasal